GSK PLCGSK PLCGSK PLC

GSK PLC

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪1.42 T‬MXN
30.63MXN
‪104.05 B‬MXN
‪640.33 B‬MXN
‪2.04 B‬
Beta (1Y)
0.31
Employees (FY)
‪70.21 K‬
Change (1Y)
+812 +1.17%
Revenue / Employee (1Y)
‪536.93 K‬MXN
Net income / Employee (1Y)
‪87.25 K‬MXN

About GSK PLC ORD GBP0.3125


CEO
Emma N. Walmsley
Headquarters
London
Website
FIGI
BBG00JX0NSM0
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
G
XS114760579
GLAXOSM.CAP. MTN 14/24
Yield to maturity
6.49%
Maturity date
Dec 2, 2024
G
17RI
GLAXOSMITHKLINE CAPITAL PLC 4.25% GTD SNR EMTN 18/12/45
Yield to maturity
6.06%
Maturity date
Dec 18, 2045
G
XS217060907
GLAXOSM.CAP. MTN 20/35MTN
Yield to maturity
5.76%
Maturity date
May 12, 2035
G
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043
Yield to maturity
5.54%
Maturity date
Mar 18, 2043
G
83GI
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 10/04/2042
Yield to maturity
5.27%
Maturity date
Apr 10, 2042
G
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038
Yield to maturity
4.96%
Maturity date
May 15, 2038
G
71ZC
GLAXOSMITHKLINE CAPITAL PLC 6.375% GTD SNR EMTN 09/03/39
Yield to maturity
4.92%
Maturity date
Mar 9, 2039
G
GSK4632357
GlaxoSmithKline Capital, Inc. 3.625% 15-MAY-2025
Yield to maturity
4.84%
Maturity date
May 15, 2025
G
US377373AH8
GLAXOSM.CAP. 19/29
Yield to maturity
4.67%
Maturity date
Jun 1, 2029
G
XS217060184
GLAXOSM.CAP. MTN 20/28MTN
Yield to maturity
4.59%
Maturity date
Oct 12, 2028
G
72WI
GLAXOSMITHKLINE CAPITAL INC 5.375% GTD SNR NTS 15/04/2034
Yield to maturity
4.58%
Maturity date
Apr 15, 2034

Explore more bonds 

Curated watchlists where GSK/N is featured.

Frequently Asked Questions


The current price of GSK/N is 707.00 MXN — it has decreased by −3.81% in the past 24 hours. Watch GSK PLC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange GSK PLC stocks are traded under the ticker GSK/N.
GSK/N stock has fallen by −3.23% compared to the previous week, the month change is a −6.77% fall, over the last year GSK PLC has showed a 15.22% increase.
We've gathered analysts' opinions on GSK PLC future price: according to them, GSK/N price has a max estimate of 1,282.67 MXN and a min estimate of 607.10 MXN. Watch GSK/N chart and read a more detailed GSK PLC stock forecast: see what analysts think of GSK PLC and suggest that you do with its stocks.
GSK/N stock is 6.03% volatile and has beta coefficient of 0.31. Track GSK PLC stock price on the chart and check out the list of the most volatile stocks — is GSK PLC there?
Today GSK PLC has the market capitalization of ‪1.43 T‬, it has increased by 0.29% over the last week.
Yes, you can track GSK PLC financials in yearly and quarterly reports right on TradingView.
GSK PLC is going to release the next earnings report on Feb 5, 2025. Keep track of upcoming events with our Earnings Calendar.
GSK/N earnings for the last quarter are 25.48 MXN per share, whereas the estimation was 22.70 MXN resulting in a 12.25% surprise. The estimated earnings for the next quarter are 10.57 MXN per share. See more details about GSK PLC earnings.
GSK PLC revenue for the last quarter amounts to ‪205.38 B‬ MXN, despite the estimated figure of ‪207.22 B‬ MXN. In the next quarter, revenue is expected to reach ‪205.37 B‬ MXN.
GSK/N net income for the last quarter is ‪−1.49 B‬ MXN, while the quarter before that showed ‪27.15 B‬ MXN of net income which accounts for −105.47% change. Track more GSK PLC financial stats to get the full picture.
GSK PLC dividend yield was 3.87% in 2023, and payout ratio reached 47.48%. The year before the numbers were 3.88% and 14.90% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 28, 2024, the company has ‪70.21 K‬ employees. See our rating of the largest employees — is GSK PLC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GSK PLC EBITDA is ‪225.64 B‬ MXN, and current EBITDA margin is 30.62%. See more stats in GSK PLC financial statements.
Like other stocks, GSK/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GSK PLC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GSK PLC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GSK PLC stock shows the neutral signal. See more of GSK PLC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.